UiPath (PATH) stock slides after Q4 FY26 results as Needham upgrades to Buy on ARR and free cash flow growth; AI ARR hits $200M.
It's still too early to say whether UiPath will ultimately end up, on net, as benefitting from or being harmed by AI adoption. Read why PATH stock is a Sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results